Kidney Cancer

The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.

Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.

The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

Patients with RCC who received 100 mg once daily casdatifan had an ORR of 33%, and those who received casdatifan plus cabozantinib had an ORR of 46%.

Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.

Panelists discuss how upcoming studies at ASCO 2025 could change practice in kidney, bladder, and prostate cancer, highlighting research on novel drug combinations, biomarkers, organ-sparing approaches, and AI-driven treatment selection.

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.